Evaluation and Control of Genotoxic Impurities in Active Pharmaceutical Ingredients

Zhang Huimi

Abstract:OBJECTIVE To provide a general overview of the regulatory guidelines on the control of genetoxic impurities in Active Pharmaceutical Ingredients, and provide some practical advices for following guidelines. METHODS Literatures about the topic of genotoxic impurities from databases such as Pubmed, Medline, websites of EMA, U.S.FDA and ICH were searched, then analysized and compared the current guidelines on this topic, and provided a controlling strategy for these impurities. RESULTS The guidelines of EMA, U.S.FDA and ICH(current step 2) maintained consistent in critical principles such as threshold of toxicological concern(TTC), risk assessment and the classification system for impurities. But the difference on other aspects between current guidelines of EMA and U.S.FDA would get them difficult to be implemented in a consistent manner for pharmaceutical manufacturers. and ICH M7, now the step 2 version, would provide a practical framework that could be applied for the control of genotoxic impurities. CONCLUSION The current guidelines can not provide a perfect strategy for the control of genotoxic impurities, and the ICH M7 that may replace the current guidelines of EMA and U.S.FDA, and will provide a better way for the pharmaceutical manufacturers to control the genotoxic impurities.

Medicine,Chemistry